Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Elevatebio Technologies Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This spread indicates that the company's active matters are not confined to a single examiner or art unit, which is a notable characteristic of their current prosecution profile.
COLEMAN, BRENDA LIBBY is identified as the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. While the workload is split between 2 distinct examiners, the presence of 2 distinct art units means that the company must navigate different sets of technical standards simultaneously. This structure requires a multifaceted legal strategy to ensure consistency across the portfolio.
For practitioners, the involvement of 2 distinct examiners in the Biotechnology & Pharmaceuticals sector necessitates a coordinated approach. The 2 pending office actions represent the current priorities for the company's intellectual property development. By analyzing the specific requirements of each art unit and the tendencies of COLEMAN, BRENDA LIBBY, the applicant can better manage the complexities of the prosecution.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276527 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | COLEMAN, BRENDA LIBBY | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004151 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING USING CIRCULAR RNA | ROGERS, ERIC JASON | 7d |
| 18276527 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | COLEMAN, BRENDA LIBBY | 40d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276527 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §102§112 | Final Rejection | 40d | Pending | Aug 09, 2023 |
| 18004151 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING USING CIRCULAR RNA | ROGERS, ERIC JASON | 1638 | §102§103§112DP | Final Rejection | 7d | Pending | Jan 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial